Substitute House Bill No. 6062 aims to prohibit direct-to-consumer advertisements for legend drugs, which are prescription medications that require a licensed practitioner to dispense. The bill defines key terms such as "consumer," "legend drug," and "prescribing practitioner," and establishes that no person engaged in trade or commerce in Connecticut may directly advertise these drugs to consumers. However, it allows pharmaceutical manufacturers registered with the Department of Consumer Protection (DCP) to promote or provide information about legend drugs to prescribing practitioners through their pharmaceutical representatives. The bill also empowers the DCP to adopt regulations for its implementation and classifies violations as unfair or deceptive trade practices under the Connecticut Unfair Trade Practices Act (CUTPA).

The bill is set to take effect on October 1, 2025, and will incur costs for the state, including the hiring of additional staff at the DCP to handle the anticipated increase in complaints and enforcement actions. Specifically, it is projected to cost $165,000 in FY 26 and $210,000 in FY 27, along with associated fringe benefits costs. The bill's provisions are designed to enhance consumer protection by limiting the direct marketing of prescription drugs, thereby potentially reducing the influence of advertising on consumer medication choices.